News Esperion and Daiichi Sankyo square up on Nexletol milestone Companies can't see eye to eye on the recently reported data from the CLEAR outcomes study.
News Nexletol shows CLEAR benefit in cardiovascular outcome trial Will a 13% improvement in MACE over placebo be enough to lift lacklustre sales growth?
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
